The Baker Department of Cardiometabolic Health is an exciting new collaboration between the Melbourne Medical School and the Baker Heart and Diabetes Institute. This initiative will leverage both organisations’ strengths in cardiometabolic capabilities and collaboration.
Cardiometabolic dysfunction describes the interrelationships between a cluster of conditions that result in people with diabetes being disproportionately at risk of heart attack and stroke. This is a global health challenge affecting millions of people, in high-income countries but also low to middle income countries (LMICs), where lifestyle changes are encouraging the rise of chronic diseases and co-morbidities.
Heart disease is the leading killer of Australians, and diabetes is the fastest-growing chronic condition in Australia. Controlling risk factors for cardiovascular disease (CVD), such as insulin resistance, obesity, high cholesterol, and hypertension, as well as finding new approaches to diagnosis and treatment for these diseases key to reducing death and disability.
This new Department will focus on research and innovation to improve the lives of people with, or at risk of, cardiovascular disease (CVD), obesity and diabetes. This work will include:
- Developing novel targets and therapeutics
- Using big data and new technologies, such as genomics, to transform prevention, diagnosis and disease management
- A focus on clinical translation
- Contributing to clinical service delivery and prevention.
Since 1926, the Baker Heart and Diabetes Institute has established a strong track record of scientific discovery and translation of these findings to improve the prevention, diagnosis and treatment of cardiovascular disease, diabetes and related conditions. The Baker Institute research has paved the way for the recognition of two types of diabetes, the introduction of beta blockers and may other innovations in treatment and prevention.
The Melbourne Medical School at the University of Melbourne is internationally renowned for global leadership in teaching and training, health research, policy and practice. We are at the heart of Australia’s premier biomedical cluster, the Melbourne Biomedical Precinct – whose 30+ partner institutions include major hospitals, including the Royal Melbourne Hospital and Austin Health – and research institutes and other organisations.